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ABSTRACT
The nucleotide-sugar–activated P2Y14 receptor (P2Y14-R) is highly
expressed in hematopoietic cells. Although the physiologic func-
tions of this receptor remain undefined, it has been strongly
implicated recently in immune and inflammatory responses.
Lack of availability of receptor-selective high-affinity antag-
onists has impeded progress in studies of this and most of
the eight nucleotide-activated P2Y receptors. A series of mole-
cules recently were identified by Gauthier et al. (Gauthier et al.,
2011) that exhibited antagonist activity at the P2Y14-R. We
synthesized one of these molecules, a 4,7-disubstituted 2-
naphthoic acid derivative (PPTN), and studied its pharma-
cological properties in detail. The concentration-effect curve
of UDP-glucose for promoting inhibition of adenylyl cyclase
in C6 glioma cells stably expressing the P2Y14-R was shifted
to the right in a concentration-dependent manner by PPTN.
Schild analyses revealed that PPTN-mediated inhibition fol-
lowed competitive kinetics, with a KB of 434 pM observed. In
contrast, 1 mMPPTN exhibited no agonist or antagonist effect at
the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors.
UDP-glucose–promoted chemotaxis of differentiated HL-60
human promyelocytic leukemia cells was blocked by PPTN
with a concentration dependence consistent with the KB
determined with recombinant P2Y14-R. In contrast, the che-
motactic response evoked by the chemoattractant peptide
fMetLeuPhe was unaffected by PPTN. UDP-glucose–promoted
chemotaxis of freshly isolated human neutrophils also was
blocked by PPTN. In summary, this work establishes PPTN as
a highly selective high-affinity antagonist of the P2Y14-R that is
useful for interrogating the action of this receptor in physiologic
systems.
Introduction
Extracellular nucleotides interact with at least 15 differ-
ent cell surface receptors to regulate a panoply of cell
signaling and physiologic responses (Ralevic and Burnstock,
1998; Burnstock, 2007). Seven of these are G protein–coupled
receptors (GPCRs) that are solely activated by nucleotides
(Abbracchio et al., 2006; von Küglegen and Harden, 2012) and
include the ADP-activated P2Y1 receptor (P2Y1-R), P2Y12-R,
and P2Y13-R; the ATP-activated P2Y11-R; the UDP-activated
P2Y6-R; the UTP-activated P2Y4-R; and the ATP- and UTP-
activated P2Y2-R. An eighth member of this structural and
functional family of GPCR, the P2Y14-R, is uniquely activated
by UDP-glucose and other nucleotide sugars (Chambers et al.,
2000; Harden et al., 2010), although recent work revealed that
this receptor is also activated potently by UDP (Carter et al.,
2009).
The P2Y14-R also is relatively distinct among the P2Y
receptors because of its limited but very high level of ex-
pression in a few tissues, including several areas of the brain,
the gastrointestinal tract, and cells of the immune and in-
flammatory response axes (Chambers et al., 2000; Freeman
et al., 2001; Lee et al., 2003; Moore et al., 2003; Skelton et al.,
2003). Human neutrophils express large amounts of P2Y14-R
mRNA (Moore et al., 2003), and incubation of neutrophils with
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UDP-glucose results in phosphorylation of ERK1/2 (Scrivens and
Dickinson, 2006; Fricks et al., 2008). Although the function of
this receptor in neutrophils and other pro-inflammatory cells
remains uncertain, insight is accruing. For example, UDP-
glucose promotes activation of Rho in human neutrophils, and
this cell signaling response was accompanied by cytoskeletal
rearrangement, alteration in cell shape, and an increase in
chemotaxis toward a gradient of UDP-glucose (Sesma et al.,
2012). These cellular responses to agonist were completely
blocked by an inhibitor of Rho kinase. Studies with P2Y14-R
knockout mice recently revealed that the P2Y14-R plays a key
role in recruitment of macrophages to liver, local inflammation,
and induction of insulin resistance that occur in a high fat
model of obesity and type 2 diabetes (Xu et al., 2012).
UDP-glucose is present in high concentrations in the se-
cretory pathway and is released from most cells as a compo-
nent of the secretory machinery (Lazarowski et al., 2003,
2011; Sesma et al., 2009). Nucleotide sugars are resistant to
hydrolysis by the nucleotide-hydrolyzing ecto-nucleoside di-
and tri-phosphohydrolases (Zimmermann, 2000), and there-
fore, high concentrations of UDP-glucose can occur in the
extracellular milieu of, for example, mucin-secreting airway
epithelial cells (Kreda et al., 2007; Okada et al., 2011) and
lung secretions in patients with cystic fibrosis (Sesma et al.,
2009; Lazarowski et al., 2011). Thus, we and others have
hypothesized that UDP-glucose functions as an extracellular
pro-inflammatory mediator, and the P2Y14-R on neutrophils
and, possibly, other immune cells functions as a key cell surface
gate-keeper in this action.
A general lack of receptor-selective molecular probes has
proved to be an obstacle to elucidation of the function of P2Y
receptors in mammalian physiology and pathophysiology.
Fully reliable antagonist molecules exist for only two (the
ADP-activated P2Y1-R and P2Y12-R) of the eight P2Y re-
ceptors (von Küglegen and Harden, 2011; Jacobson et al.,
2012). Availability of a receptor-selective antagonist for the
P2Y14-R receptor is crucial for elucidation of the role(s) played
by this signaling protein in inflammatory/immune responses.
To this end, two classes of molecules recently were found by
Black and colleagues to act as antagonists of the P2Y14-R, and
these hits were structurally modified to enhance receptor
affinity (Gauthier et al., 2011; Guay et al., 2011; Robichaud
et al., 2011). We now have studied one of these optimized
compounds in detail. We illustrate that this drug acts as a
high-affinity competitive antagonist of the P2Y14-R and does
so without interacting with any of the other seven P2Y re-
ceptor subtypes. Of importance, this antagonist blocks UDP-
glucose–promoted chemotaxis of human neutrophils. We
conclude that this molecular probe will be highly useful for
further interrogation of the functional role(s) played by the
P2Y14-R in mammalian physiology and pathophysiology.
Materials and Methods
Synthesis of 4-((Piperidin-4-yl)-Phenyl)-7-(4-(Trifluoromethyl)-
Phenyl)-2-Naphthoic Acid. A 2-naphthoic acid derivative 4-
((piperidin-4-yl)-phenyl)-7-(4-(trifluoromethyl)-phenyl)-2-naphthoic acid
(PPTN) was synthesized as described elsewhere (Belly et al., 2009;
Gauthier et al., 2011). In brief, the starting material (1, Fig. 1),
prepared as described (Boger et al., 1996), was subjected to a Suzuki
coupling, and the resulting phenol 2 converted to the triflate 3. After
boronation, a second Suzuki coupling produced 5, which was reduced
and deprotected (two steps) to provide the desired product PPTN, 6.
The 1H-NMR and high-resolution mass spectrum of 6 was consistent
with the assigned structure. PPTNwas used as dimethylsulfoxide stock
solution (5 mM), which was stable to storage at 4°C. Additional details
of the chemical synthesis are provided (Supplemental Experimental
Procedures).
P2Y-R Cell Lines. Stable 1321N1 human astrocytoma cell lines
individually expressing the P2Y1-R, P2Y2-R, P2Y4-R, P2Y6-R, or
P2Y11-Rwere generated as previously described (Nicholas et al., 1996;
Schachter et al., 1996; Qi et al., 2001). C6 rat glioma cells stably
expressing the P2Y14-R and Chinese hamster ovary (CHO) cells stably
expressing the P2Y12-R were generated as previously described
(Fricks et al., 2009).
Cell Culture. All cell lines were maintained at 37°C and at 5%
CO2. C6 cells were cultured in F-12 medium supplemented with 10%
fetal bovine serum (FBS). CHO cells weremaintained in F-12medium
with 10%FBS and 1% geneticin, and 1321N1 cells weremaintained in
Dulbecco’s modified Eagle’s medium (DMEM) with 5% FBS and 1%
geneticin. HL-60 promyeloleukemia cells were maintained in RPMI
1640 medium supplemented with 10% FBS. Differentiation of HL-60
cells (dHL-60 cells) was performed by adding 1.3% dimethylsulfoxide
to the medium for 5 days.
Quantification of Cyclic AMP Accumulation. Cells were
plated in 24-well plates approximately 24 hours before the assay
and were labeled 2 hours before the assay with 1 mCi [3H]adenine/well
in 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)-
buffered serum-free DMEM. All assays were in the presence of 200 mM
3-isobutyl-1-methylxanthine (IBMX) and were initiated by the
addition of 30 mM forskolin, agonists, and/or PPTN. Incubations were
for 15 minutes at 37°C and were terminated by aspiration of medium
and addition of 500 ml ice-cold 5% trichloroacetic acid. [3H]Cyclic AMP
was isolated by sequential Dowex and alumina chromatography
(Salomon et al., 1974), as previously described (Harden et al., 1982).
Inositol Phosphate Accumulation in Cell Lines Stably
Expressing P2Y Receptors. Stable 1321N1 human astrocytoma
cell lines for each of the Gq/phospholipase C–coupled P2Y receptors
(i.e., P2Y1-1321N1, P2Y2-1321N1, P2Y4-1321N1, P2Y6-1321N1, and
P2Y11-1321N1 cells) were used in experiments designed to examine
the P2Y-R subtype selectivity of PPTN. Cells were plated (20,000
cells/well) in 96-well plates two days before assay, and 16 hours before
the assay, the inositol lipid pool of the cells was radiolabeled by
incubation in 100 ml of serum-free inositol-free DMEM containing
1.0 mCi of myo-[3H]inositol. Incubations with drugs were in 20 mM
HEPES (pH 7.4)–buffered Hanks’ balanced salt solution (HBSS)
containing 10 mM LiCl and were terminated after 30 minutes at 37°C
by aspiration of the medium and addition of 50 mM formic acid. The
samples were neutralized with 150 mM ammonium hydroxide, and
[3H]inositol phosphate accumulation was quantified using Dowex
chromatography and liquid scintillation counting, as previously
described (Brown et al., 1991).
Inositol Phosphate Accumulation in Transiently Trans-
fected Cells. COS-7 cells were plated in 12-well plates at 65,000
cells per well and were transfected 24 hours later with expression
vectors for Gaq/i and either the human P2Y13-R or P2Y14-R. Twenty-
four hours after transfection, the cells were labeled with 1 mCi ofmyo-
[3H]inositol in 400 ml of serum-free inositol-free DMEM. Quantification
of [3H]inositol phosphate accumulation in the presence of drugs was
accomplished as described above for the stable P2Y-R cell lines.
Purification of Human Neutrophils. Fresh venous blood
samples were obtained from healthy male and female volunteers
with written informed consent and the approval of the University of
North Carolina Institutional Review Board. Neutrophils were isolated
(.98% purity) using Ficoll-paque Plus (GE Healthcare, Waukesha,
WI) and 3% dextran as described previously (Sesma et al., 2012). The
isolated neutrophils were rinsed and resuspended (1  106 cells/ml)
in RPMI medium supplemented with 10% heat-inactivated FBS.
Apyrase (1U/ml)was included in the isolation steps to removenucleotides
potentially released from damaged or mechanically activated neutrophils
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(e.g., during cell washes and centrifugation) and, thus, to avoid
unwanted activation of P2Y2-R or P2X1-R expressed in these cells
(Verghese et al., 1996; Vaughan et al., 2007; Lecut et al., 2009).
Quantification of Chemotaxis. Human neutrophils were loaded
with 2.5 mM carbocyanide dye 1,1’-dioctadecyl-3,3,39,39-tetrameth-
ylindodicarbocyanine perchlorate (DID; Vybrant Cell-Labeling Solu-
tions; Invitrogen, Carlsbad, CA) for 15 minutes (106 cells/ml) in RPMI
medium supplemented with 10% heat-inactivated FBS, and dHL-60
cells were loaded with 2.5 mMDID in HEPES-buffered (pH 7.4) HBSS
supplemented with 1.6 mM CaCl2 and 0.8 mM MgCl2. Cells were
rinsed twice and suspended in RPMI or HBSS as above. Chemotaxis
was quantified in 96-multiwell FluoroBlock inserts (BD Falcon,
Franklin Lakes, NJ) as described previously (Sesma et al., 2012). In
brief, vehicle or agonist was added to the lower compartment
(225 ml), and 75-ml of a cell suspension (2 105 cells) was loaded onto
the upper compartment in the absence or presence of the indicated
amount of PPTN. The fluorescent signal (F, 612 nm excitation/
670 nm emission) was read at the indicated times with use of a Tecan
Infinite M1000 plate reader. The chemotaxis index (Ctx Index) was
defined as:
Ctx Index 5 (F1 – FB) ⁄ (F0 – FB), where F1 and F0 represent the
fluorescence signal from stimulated and unstimulated cells, respectively,
and FB is background fluorescence measured in the absence of cells.
Typical values for fluorescence in these experiments were: F(B)5 180,
F(0) 5 1000, F(UDP-glucose) 5 1300–1600; F[formyl-Met-Leu-Phe
(fMLP)] 5 2300–2500.
Data Analysis. Nonlinear regression and Schild analyses were
performed using Prism software (GraphPad Software, San Diego,
CA). All experiments were repeated at least three times.
For chemotaxis experiments, statistical analysis was performed
using analysis of variance with post hoc Tukey honestly significant
difference (P # 0.05; JMP Genomics, version 4.1; SAS, Cary, NC).
Materials. IBMX, forskolin, and apyrase were purchased from
Sigma-Aldrich (St. Louis, MO). UDP, UDP-glucose, ATP, UTP, and
2-methylthio-adenosine 59-diphosphate (2MeSADP) all were from
Fluka and were purchased from Sigma-Aldrich. [3H]Adenine and
myo-[3H]inositol were purchased from American Radiolabeled Chem-
icals (St. Louis, MO). Geneticin, serum, and all cell culture medium
were from Invitrogen.
Results
A series of recently synthesized molecules were reported to
act as antagonists of the P2Y14-R. One of these, PPTN (Fig. 1),
was synthesized as described in Materials and Methods, and
the activity and selectivity of this molecule was investigated
in detail with (1) a stable cell line that expresses the human
P2Y14-R, (2) cells expressing each of the other seven G protein–
coupled P2Y receptors, (3) HL-60 human promyelocytic leuke-
mia cells, and (4) human neutrophils.
We previously showed that UDP-glucose and UDP act as
potent agonists to inhibit forskolin-stimulated adenylyl cyclase
activity in C6 rat glioma or CHO cells stably expressing the
human P2Y14-R receptor, but these agonists have no inhibitory
effect in wild-type C6 or CHO cells (Fricks et al., 2008; Carter
et al., 2009). As shown in Fig. 2A, UDP-glucose promotes
concentration-dependent inhibition of forskolin-stimulated
cyclic AMP accumulation in P2Y14-C6 cells with an EC50 value
of ∼10 nM. We previously reported that constitutive release of
UDP-glucose occurs from many different cell lines, including
C6 cells, resulting in significant accumulation of this agonist
in the extracellular medium (Lazarowski et al., 2003). One
prediction from these previous studies is that inhibition of
adenylyl cyclase activitymay occur in P2Y14-C6 cells because of
constitutive release of UDP-glucose and that drug-mediated
blockade of the P2Y14-R would reverse this inhibition by an-
tagonizing the action of the nucleotide sugar at its cell surface
receptor. Therefore, basal and forskolin-stimulated cyclic AMP
accumulation was measured in wild-type and P2Y14-C6 cells in
the absence and presence of 100 nM PPTN. Whereas no effect
of PPTN on cyclic AMP levels was observed in wild-type C6
cells (Fig. 2B), both basal and forskolin-stimulated cyclic AMP
accumulation were elevated in P2Y14-C6 cells (Fig. 2C). Be-
cause of the effect observed in P2Y14-C6 cells, a full concentra-
tion effect curve for PPTN was performed (Fig. 3). Both basal
and forskolin-stimulated cyclic AMPaccumulationwere elevated
Fig. 1. Structure and synthetic route of PPTN. The
synthetic procedure is briefly described in Materials and
Methods and is based on Boger et al. (1996) and Belly
et al. (2009). Additional details of the procedures also are
provided (Supplemental Experimental Procedures).
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over similar concentration ranges with the maximal effect of
PPTN observed around a concentration of 100 nM. These
results are consistent with the idea that constitutively re-
leased UDP-glucose (and potentially other nucleotide-sugars)
promotes inhibition of adenylyl cyclase in P2Y14-C6 cells, and
this effect is reversed by PPTN-dependent antagonism of the
P2Y14-R.
The idea that PPTN acts as an antagonist in P2Y14-C6 cells
was tested directly by generating concentration effect curves
for UDP-glucose for inhibition of forskolin-stimulated cyclic
AMP accumulation in the presence of various concentrations
of PPTN (Fig. 4A). Concentrations of PPTN as low as 1 nM
antagonized the effect of UDP-glucose, and a parallel shift to
the right of the UDP-glucose concentration effect curve was
observed with increasing concentrations of PPTN. The sur-
mountable antagonism observed with PPTN over a 10,000-
fold range of concentrations is consistent with competitive
antagonism occurring at the orthosteric binding pocket of the
P2Y14-R. However, we cannot rule out involvement of an
additional mechanism, because the slopes of Schild plots from
multiple experiments were typically greater than 1.0 (Fig.
4B). This occurred whether PPTN was added simultaneously
with UDP-glucose or cells were preincubated with PPTN for
up to 30 minutes before addition of agonist. The KB value of
PPTN obtained from four separate experiments, similar to
that shown in Fig. 4B, was 434 6 126 pM.
UDP is also a cognate agonist of the P2Y14-R (Carter et al.,
2009), and as shown in Fig. 5, the capacity of this nucleotide to
inhibit adenylyl cyclase activity in P2Y14-C6 cells was blocked
by PPTN. MRS2906 (b-ethyl ester of 2-thio-UDP) was
synthesized as a high-affinity selective agonist of the P2Y14-R
(Das et al., 2010), and as was the case with the natural agonists
of this receptor, its activity also was blocked by PPTN (Fig. 5).
Taken together, these results reveal that PPTN is a potent
competitive antagonist of the orthosteric binding site of the
P2Y14-R.
The receptor selectivity of PPTN is not known, and there-
fore, we examined the possibility that this molecule might
also interact with additional P2Y receptor subtypes. The
capacity of agonists (2MeSADP, UTP, UTP, UDP, and ATP) of
the human P2Y1-R, P2Y2-R, P2Y4-R, P2Y6-R, and P2Y11-R,
respectively, to promote activation of Gq-regulated phospho-
lipase C was examined in stable 1321N1 human astrocytoma
cell lines generated for each one of these receptors (i.e., P2Y1-
1321N1, P2Y2-1321N1, P2Y4-1321N1, P2Y6-1321N1, and
P2Y11-1321N1 cells). With each cell line, the effects on ino-
sitol phosphate accumulation of various concentrations of
PPTN were determined in the absence of agonist or in the
presence of a concentration of agonist that produced approx-
imately 80% of the maximal stimulation observed with that
agonist. No effect of PPTN alone on inositol phosphate ac-
cumulation was observed at concentrations up to 10 mM in
Fig. 2. PPTN blocks P2Y14-R–dependent elevation of cyclic AMP levels in P2Y14-C6 cells. (A) Cyclic AMP accumulation was quantified in P2Y14-C6 cells
in the presence of 30 mM forskolin and the indicated concentrations of UDP-glucose (UDPG) as described in Materials and Methods. The results are the
mean of triplicate determinations and are representative of results of at least three separate experiments. (B) Basal and forskolin (30 mM)–stimulated
cyclic AMP accumulation was quantified in the absence or presence of 1 mM PPTN in wild-type (WT) C6 glioma cells. The results are the mean of
triplicate determinations and are representative of results of three separate experiments. (C) Basal and forskolin (30 mM)–stimulated cyclic AMP
accumulation was quantified in the absence or presence of 100 nM PPTN in P2Y14-C6 glioma cells. The results are the mean of triplicate determinations
and are representative of results of three separate experiments. NS, not significant; (*) and (#), significantly different from vehicle and forskolin,
respectively; P , 0.05 by unpaired t test.
Fig. 3. Concentration-dependent effect of PPTN on cyclic AMP levels in
P2Y14-C6 cells. Basal and forskolin (30 mM)–stimulated cyclic AMP
accumulation was quantified in the presence of the indicated concen-
trations of PPTN in P2Y14-C6 glioma cells. The results are the mean of
triplicate determinations and are representative of results of at least three
separate experiments.
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any of these P2Y receptor–expressing stable cell lines (Fig. 6).
Moreover, none of the concentrations of PPTN up to 10 mM
affected the capacity of agonists to activate their respective
Gq/phospholipase C–linked P2Y receptor.
The potential capacity of PPTN to interact with the ADP-
activated P2Y12-R and P2Y13-R also was examined. Similar
to the P2Y14-R, both of these receptors are Gi-coupled. In
the case of the P2Y12-R, a stable cell line is available,
and therefore, we tested the potential activity of PPTN to
antagonize 2MeSADP-promoted inhibition of adenylyl
cyclase in P2Y12-CHO cells. Concentrations of PPTN as
high as 1 mM exhibited no effect on forskolin-stimulated cyclic
AMP accumulation in P2Y12-CHO cells (Fig. 7A). Moreover, the
capacity of an approximately EC80 concentration of ADP for
promoting P2Y12-R–dependent inhibition of forskolin-stimulated
cyclic AMP accumulation in these cells was not affected by
concentrations of PPTN up to at least 1 mM.
No stable cell line for the human P2Y13-R was available,
and therefore, we transiently co-expressed the human P2Y13-R
in COS-7 cells with a G protein construct Gaq/i that confers
capacity of Gi-coupled receptors to activate phospholipase C
(Coward et al., 1999). As shown in Fig. 7B, concentrations of
PPTN up to 10 mM had no effect on basal inositol phosphate
accumulation in these cells. Moreover, PPTN at concentra-
tions as high as 3 mM exhibited no effect on the capacity of an
EC80 concentration of 2MeSADP to activate the P2Y13-R.
Because the receptor-promoted signaling responses measured
in this engineered test system do not occur through com-
ponents of the native G protein signaling pathway, we also
confirmed the antagonist activity of PPTN at the human
P2Y14-R in COS-7 cells using the same inositol lipid signaling
response system engineered by transient coexpression with
Gaq/i. As was observed with quantification of activity in P2Y14-
R-C6 cells above, low nM concentrations of PPTN inhibited
the capacity of UDP-glucose to promote P2Y14-R–dependent
inositol lipid signaling in the COS-7 cell transfection system
(Fig. 7B).
Taken together, these studies with recombinant systems
shown that PPTN is a potent competitive inhibitor of the
P2Y14-R. Conversely, this molecular probe at .1000-fold
higher concentrations has no measureable effect on the other
seven P2Y receptors.
We previously reported that differentiation of HL-60
human promyelocytic leukemia cells results in up-regulation
of the P2Y14-R and confers cell signaling responses of these
cells to UDP-glucose (Fricks et al., 2009). Moreover, exposure
Fig. 4. High-affinity competitive antagonism of the human P2Y14-R by
PPTN. (A) Concentration effect curves for UDP-glucose (UDPG) for
inhibition of forskolin (30 mM)–stimulated cyclic AMP accumulation were
generated in P2Y14-C6 glioma cells in the presence of the indicated
concentrations of PPTN. The data are the mean of triplicate determi-
nations, and the results are similar to those obtained in four separate
experiments. Typical values for basal and forskolin-stimulated [3H]cyclic
AMP accumulation were approximately 1000 and 9000 cpm, respectively.
(B) A Schild plot was generated by determining the dose ratio (con-
centration of agonist necessary to produce a chosen level of effect in the
presence of the indicated concentration of PPTN divided by the con-
centration of agonist that produces the same effect in the absence of an-
tagonist) for each concentration of antagonist and then plotting log (dose
ratio -1) on the Y-axis versus concentration of antagonist presented on
the X-axis. The KB determined from the intercept of the regressed line on
the X- axis was 1150 pM, and a slope of 0.91 was observed. The results are
similar to those obtained in four separate experiments.
Fig. 5. PPTN blocks the agonist action of UDP and a receptor-selective
synthetic analog at the P2Y14-R. Forskolin (30 mM)–stimulated cyclic
AMP accumulation was quantified in P2Y14-C6 cells in the presence of
1 mM UDP-glucose (UDPG), UDP, or MRS2906 with or without 300 nM
PPTN. The results are from triplicate determinations and are represen-
tative of results from three different experiments.
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of dHL-60, but not undifferentiated HL-60 cells, to a gradient
of UDP-glucose results in chemotaxis (Sesma et al., 2012).
Thus, we examined the capacity of PPTN to block UDP-
glucose–promoted chemotaxis of dHL-60 cells with use of
a modified Boyden chamber. As we previously reported in
detail (Sesma et al., 2012), addition of UDP-glucose to the
lower compartment of the chemotaxis chamber resulted in
a pronounced migration of dHL-60 cells from the upper
chamber (Fig. 8A). The EC50 of UDP-glucose for producing
this effect was approximately 1 mM (Sesma et al., 2012;
unpublished data). The concentrations shown in Fig. 8A
should be considered to be nominal concentrations of agonist
for activation of the P2Y14-R in this test system, because the
actual concentration of UDP-glucose reaching the cells in the
upper chamber is considerably lower. Using this physiologic
test system, we examinedwhether the effects of PPTNacting as
a competitive antagonist of the P2Y14-R were recapitulated in
measurements of UDP-glucose–promoted chemotaxis. Addition
of PPTN to the upper chamber caused a concentration-
dependent inhibition of the effects of 10 and 100 mM UDP-
glucose with complete inhibition of agonist-promoted effects
observed with approximately 100 nM PPTN (Fig. 8B). De-
termination of an accurate Ki value for PPTN is not technically
feasible in this test system. However, the IC50 values observed
for PPTN (∼1 nM in the presence of 10 mM UDP-glucose and
∼4 nM in the presence of 100 mM) are consistent with the
relative affinity determined for PPTN by Schild analyses in
P2Y14-C6 cells. We also observed that the effect on chemotaxis
of adding 10 mM UDP-glucose to the lower chamber was
blocked by 100 nM PPTN, irrespective of whether antagonist
was added to the upper, lower, or both chambers simulta-
neously (unpublished data). The selectivity of PPTN in the
dHL-60 cell test system was examined by studying its effect on
chemotaxis stimulated through activation of another GPCR.
Thus, the capacity of fMLP to promote chemotaxis was
examined in the presence of 100 nM PPTN. As shown in Fig.
Fig. 6. Lack of effect of PPTN at the P2Y1-R, P2Y2-R, P2Y4-R, P2Y6-R,
and P2Y11-R. [
3H]Inositol phosphate accumulation was determined in
P2Y1-1321N1 (red), P2Y2-1321N1 (blue), P2Y4-1321N1 (green), P2Y6-
1321N1 (purple), and P2Y11-1321N1 (black) cells in the absence of agonist
(open symbols) or in the presence of a concentration of the cognate agonist
(closed symbols) for each receptor that produced approximately 70–80% of
the maximal effect observed with that agonist. The agonists and their
concentrations were 2MeSADP (1 mM), UTP (300 nM), UTP (1 mM), UDP
(1 mM), and ATP (100 mM) for the P2Y1-R, P2Y2-R, P2Y4-R, P2Y6-R, and
P2Y11-R, respectively. The results are the mean of triplicate determina-
tions and are representative of results of at least three different experi-
ments for each receptor. Typical values for basal and agonist-stimulated
[3H]inositol phosphate accumulation were approximately 1000 and
6000 cpm, respectively, for P2Y1-1321N1 cells, approximately 3000 and
10,000 cpm, respectively, for P2Y2-1321N1 cells, approximately 3000
and 14,000 cpm, respectively, for P2Y4-1321N1 cells, approximately 3000
and 25,000 cpm, respectively, for P2Y6-1321N1 cells, and approximately
1000 and 8000 cpm, respectively, for P2Y11-1321N1 cells.
Fig. 7. Lack of effect of PPTN at the P2Y12-R and P2Y13-R. (A) Forskolin
(30 mM)–stimulated cyclic AMP accumulation was quantified in P2Y12-
CHO cells in the presence of the indicated concentrations of PPTN in
the absence (open red circle) or presence (closed red circle) of 1 mM
2MeSADP. The results are the mean of triplicate determinations and
are representative of results of at least three different experiments
for each receptor. Typical values for basal and forskolin-stimulated
[3H]cyclic AMP accumulation in P2Y12-CHO cells were approximately
700 and 4000 cpm, respectively. Data from Fig. 4 were replotted (dotted
blue line) to provide a comparative illustration of the concentration-
dependent effects of PPTN for antagonizing the effect of 316 nM UDP-
glucose at the P2Y14-R. (B) Agonist-stimulated [
3H]inositol phosphate
accumulation was quantified in the presence of the indicated concen-
trations of PPTN in the absence (open symbols) or presence (closed
symbols) of agonists in COS-7 cells transfected with expression vectors for
Gaq/i and the human P2Y13-R (green) or P2Y14-R (blue). The agonists used
were 3 mM ADP and 1 mM UDP-glucose for the P2Y13-R and P2Y14-R,
respectively. The results are the mean of triplicate determinations and
are representative of results of at least three different experiments for
each receptor.
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8C, the P2Y14-R antagonist had no significant effect on
chemoattractant peptide-promoted chemotaxis.
P2Y14-R mRNA is highly expressed in human neutrophils
(Chambers et al., 2000; Freeman et al., 2001; Lee et al., 2003;
Moore et al., 2003), and as we recently demonstrated (Sesma
et al., 2012), UDP-glucose promotes activation of Rho,
cytoskeletal rearrangement, change of cell shape, and
chemotaxis of these cells. Thus, as is shown in Fig. 9,
addition of 100 mMUDP-glucose to the lower chamber caused
a robust migration of human neutrophils. This effect was
largely inhibited by addition of 100 nM PPTN to the upper
chamber.
Discussion
The P2Y14-R is increasingly implicated in inflammatory
and immune responses, and we reveal here that PPTN is
a high-affinity competitive antagonist of this receptor that
exhibits strong selectivity for the P2Y14-R over the other
seven nucleotide-activated P2Y receptors. PPTN-dependent
blockade of UDP-glucose–promoted chemotaxis of human
neutrophils suggests that this molecule or its analogs will be
useful for interrogation of P2Y14-R–mediated physiologic
responses in vivo.
High-affinity competitive antagonists were developed for
the P2Y1-R, and both competitive and noncompetitive an-
tagonists are available for the P2Y12-R. However, such highly
selective probes have not been available for the other sub-
types of P2Y-R, and thus, the work of Black and colleagues,
recently identifying potential antagonist molecules for the
P2Y14-R, is promising (Gauthier et al., 2011; Guay et al., 2011;
Robichaud et al., 2011). High-throughput screens measuring
small molecule–dependent inhibition of UDP-glucose–stimu-
lated Ca21 mobilization in P2Y14-R–expressing HEK cells
identified dihydropyridopyrimidine (Guay et al., 2011) and
naphthoic acid–containing (Gauthier et al., 2011) molecules
as potential P2Y14-R inhibitors. In both cases, directed syn-
thesis led to molecules that inhibited P2Y14-R–promoted Ca
21
responses in the nanomolar range of concentrations. It was con-
cluded on the basis of lack of inhibition of [3H]UDP binding that
the dihydropyridopyrimidine derivatives were noncompetitive
inhibitors of the P2Y14-R (Guay et al., 2011). Conversely,
several of the naphthoic acid derivatives, including PPTN,
inhibited [3H]UDP binding with apparent binding affinities in
the low nanomolar range of concentrations (Gauthier et al.,
2011; Robichaud et al., 2011). Of interest, one of the highest ap-
parent affinity naphthoic acid derivatives also bound with high
affinity to serum proteins, and therefore, PPTNwas identified
as a naphthoic acid derivative that bound with high apparent
affinity to the P2Y14-R but exhibited less robust human serum
albumin binding (Robichaud et al., 2011). A prodrug deriva-
tive of PPTN (an ester of the carboxylic acid) also was pre-
pared to enhance its bioavailability. Only [3H]UDP binding
Fig. 8. PPTN inhibits UDP-glucose–promoted chemotaxis in differentiated HL-60 human promyelocytic leukemia cells. (A) Chemotaxis of dHL-60 cells
was quantified in the presence of 1, 10, and 100 mMUDP-glucose (UDPG). The agonist was added to the lower compartment of a Boyden chamber. After 2
hours of incubation at 37°C, the fluorescence of the bottom compartment was read and expressed as chemotaxis index (seeMaterials and Methods). The
results are the mean 6 S.E.M. of three independent experiments, each one performed in quadruplicate. (B) dHL-60 cells were added to the upper
compartment in the presence of the indicated concentrations of PPTN, and chemotaxis index was quantified as above in the presence of either 10 mM or
100 mMUDP-glucose added to the lower compartment. The data are the mean6 S.E.M. of results from three independent experiments, each performed
in quadruplicate. (C) The effect of PPTN on fMLP-induced chemotaxis was quantified. Vehicle or 100 nM fMLPwas added to the lower compartment, and
dHL-60 cells were added with or without 100 nM PPTN to the upper compartment. The results are the mean6 S.E.M. from three separate experiments,
each performed in quadruplicate. NS, not significantly different from fMLP alone.
Fig. 9. PPTN inhibits UDP-glucose–promoted chemotaxis in human
neutrophils. Neutrophil migration was quantified in response to vehicle or
100mMUDP-glucose (UDPG) added to the lower compartment of a Boyden
chamber. Neutrophils were loaded in the upper chamber with or without
10 nM PPTN. The chemotaxis (Ctx) index was quantified after 2 hours, as
described in Materials and Methods. The results are the mean 6 S.E.M.
from three separate experiments, each performed in quadruplicate; (*)
and (#), significantly different from vehicle and UDP-glucose, respectively;
P , 0.05 by 2-way analysis of variance.
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was used to ascertain the P2Y14-R activity of PPTN, but
Gao et al. (2013) recently reported that 10 mM PPTN
largely blocked the effect of a synthetic P2Y14-R agonist on
b-hexosaminidase release from human LAD2 mast cells.
Hamel et al. (2011) also screened a phosphonate library
using a [3H]UDP binding assay to identify several molecules
that were concluded to bind to the P2Y14-R in the low micro-
molar range.
We previously showed that UDP-glucose is basally released
from C6 glioma and other cell lines. Because of its resistance
to ecto-NTDPases, substantial concentrations of this and other
nucleotide sugars accumulate in the extracellularmedium, and
P2Y14-R–dependent cell signaling responses ensue (Lazarowski
et al., 2003). Constitutively released nucleotide sugars would
be expected to promote P2Y14-R–mediated inhibition of basal
and forskolin-stimulated adenylyl cyclase activity in P2Y14-
R-C6 cells. Direct comparison of cyclic AMP accumulation
in wild-type versus P2Y14-R–expressing C6 cells does not
provide a precise quantitative comparison of the extent of the
P2Y14-R–dependent effect, but the relative effects observed
with PPTN do. That is, whereas PPTN exhibited no effect in
wild-type cells, it caused a concentration-dependent eleva-
tion of basal and forskolin-stimulated cyclic AMP accu-
mulation in P2Y14-R-C6 cells. The EC50 (3–10 nM) of PPTN
observed for elevation of cyclic AMP in the absence of
added UDP-glucose was considerably greater than the KB
(∼500 pM) of PPTN calculated from Schild analyses with
added UDP-glucose. This is consistent with the idea that the
majority of the effect of PPTN on cyclic AMP levels in the
absence of added agonist occurs because of blockade of
the effect of agonist released from the cells into the medium.
Our previous studies with the human P2Y14-R transiently
overexpressed in Cos-7 cells suggested the occurrence of little
if any constitutive activity of the receptor studied under those
conditions (Lazarowski et al., 2003), and stable expression of
the receptor in P2Y14-R-C6 cells from a viral vector likely
results in a lower level of receptor than that attained in Cos-7
cells. However, we cannot rule out unambiguously that
constitutive activity of the receptor occurs and that a compo-
nent of the effect of PPTN in the absence of added UDP-
glucose is attributable to inverse agonist activity of this
molecule.
Direct measurement of the capacity of PPTN to block the
effect of added UDP-glucose on adenylyl cyclase activity in
P2Y14-R-C6 cells illustrated a remarkably high affinity of this
probe for antagonism of the P2Y14-R. The apparent blockade
of the effect of basally released agonist(s) on cyclic AMP ac-
cumulation by low concentrations of PPTN also is consistent
with the KB value of this molecule determined by Schild
analyses. Both UDP and UDP-sugars are cognate agonists
of the P2Y14-R, and we show here that the actions of both
types of activating ligands are antagonized by PPTN. Ob-
viously, we cannot resolve whether it is UDP, a nucleotide
sugar, or both that mediates the basal regulation measured in
P2Y14-R-C6 cells; however, PPTN clearly would block the
action of both.
The heterocyclic precursor to PPTN was identified in an
unbiased screen of a small molecule library, and PPTN bears
no obvious resemblance to nucleotides. Thus, we might
anticipate that this molecule would exhibit selectivity, if not
specificity, for the P2Y14-R over other P2Y receptors. A three-
dimensional structure of the agonist binding pocket is not yet
available for any of the P2Y receptors. However, given the
similarity of the nucleotide ligands of these receptors, their
orthosteric binding sites almost certainly will show structural
overlap. This may be particularly true for the P2Y14-R relative
to other subtypes of the Gi-coupled P2Y12-R subgroup of P2Y
receptors. This subgroup includes the P2Y12-R, P2Y13-R, and
P2Y14-R, which exhibit relatively high (40–50%) sequence
identity overall and contain membrane-spanning regions that
are particularly highly conserved. Thus, it was important to
establish the selectivity of PPTN, and its lack of activity
observed here at any of the P2Y receptors, including the other
two subtypes of the P2Y12-R subgroup, bodes well for its
application as a selective molecular probe of the P2Y14-R. This
selectivity is of obvious importance for in vivo studies, but
cultured cell lines also predictably express multiple P2Y-R
subtypes.
The high level expression of mRNA for P2Y14-R in neu-
trophils, lymphocytes, and macrophages is consistent with a
function for this signaling protein in immune and inflam-
matory responses (Chambers et al., 2000; Freeman et al.,
2001; Lee et al., 2003; Moore et al., 2003). Early studies
proposed a role for the P2Y14-R in chemotaxis of hematopoi-
etic stem cells (Lee et al., 2003), and although Arase and
coworkers (2009) were unable to illustrate effects of UDP-
glucose on chemotaxis of neutrophils, they showed that the
P2Y14-R played a key role in the innate mucosal immunity
response of the female reproductive tract. More recently, we
directly showed that the P2Y14-R promotes Rho-mediated
signaling and chemotaxis in human neutrophils (Sesma
et al., 2012), and Xu and coworkers (2012) revealed that high-
fat diet-induced inflammatory responses of the liver are
markedly reduced in P2Y14-R(2/2) mice (Xu et al., 2012).
UDP-glucose increased migration of macrophages isolated
from wild-type mice, but had no effect in P2Y14-R knock-out
animals. Furthermore, the high-fat diet resulted in insulin
resistance, and this effect was lessened in P2Y14-R(2/2) mice.
Thus, a number of lines of investigation now indicate an
important role for extracellular nucleotide sugars and P2Y14-R
in innate immunity responses.
UDP-glucose is released concomitantlywithmucins (Hirschberg
et al., 1998) from airway epithelial goblet (mucous) cells
(Kreda et al., 2007; Okada et al., 2011), and chronic lung
diseases, such as cystic fibrosis, asthma, and chronic obstruc-
tive lung disease, are characterized by mucin hypersecretion
and inflammation. Potentially relevant to airway inflamma-
tion, UDP-glucose levels in lung secretions (i.e., bronchoalveolar
lavage fluids) from patients with cystic fibrosis are in the
range of concentrations that promote robust activation of the
P2Y14-R (Sesma et al., 2009). Thus, the pharmacological
activity and selectivity of PPTN for the P2Y14-R delineated
here using recombinant cell systems indicates that this
molecule should prove to be useful for interrogation of the
physiologic roles of the P2Y14-R in lung inflammation in
vivo. This notion is made more tangible by our observation
that PPTN blocks UDP-glucose–promoted chemotaxis of
human neutrophils and does so across a concentration range
consistent with its KB determined in the P2Y14-R–expressing
cell line.
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